News by subject: TRI

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today it has initiated the Phase 2a portion of the BGBC016 clinical study of its...

SOPHiA GENETICS , a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada. USask will implement the SOPHiA DDMtm Platform for use in its...

Pelvic Rehabilitation Medicine (PRM), the national leader in endometriosis care, believes that when it comes to endometriosis, patients don't need to go back and forth to the OR. They deserve treatment that gets them better faster and a life...

Evosep, a leading provider of sample preparation and separation solutions for mass spectrometry-based proteomics, is thrilled to announce the publication of a groundbreaking study in Nature Communications highlighting the capabilities of its...

Rafa Laboratories, LTD., a leading manufacturer of Emergency Medical Solutions, and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of...

The Business Intelligence Group today announced that OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, has been named a winner in its Artificial Intelligence Excellence Awards program in the...

While fluoride-based treatments have long been the gold standard in dentistry for preventing tooth decay, this singular approach does not sufficiently control biofilm?the main culprit behind dental caries (cavities) ?and prevent enamel...

Antennova, a clinical-stage biotech company focused on oncology today announced completion of the first dosing cohort in...

Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into an expanded strategic collaboration with Maruho Co., Ltd., to exclusively develop and...

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology...

Lucid Diagnostics Inc. ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. ( "PAVmed"), today announced that four abstracts related to its groundbreaking...

Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced groundbreaking headline results for the creation of a validated NCE, pan-antiviral library....

Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announced today that their first patient has been successfully dosed in the phase II study...

Numinus Wellness Inc. ("Numinus" or the "Company") , a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that it has submitted...

Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...

Final data from a landmark study on PainTEQ's posterior approach SI joint fusion with the LinQtm implant revealed improved pain and function scores and an excellent safety profile at 12 months post-operation....

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate...

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology...

Tempo Therapeutics, Inc ("Tempo") a leading innovator in tissue engineering and regenerative medicine, today announced the successful completion of its $12 million Series A equity financing round, led by Galaxy-Sirius Partners and Johnson & Johnson...

?   Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA under an accelerated approval pathway in the second half of 2024; ramping up commercial readiness...

Unravel Biosciences, Inc., ("Unravel"), an AI-enabled therapeutics company established to advance drugs for complex diseases, today announced a manufacturing and development partnership with Quality Chemical Laboratories, Inc. (QCL) to manufacture...

Prominently featured in The Inner Circle, Jeffrey S. Yarvis is acknowledged as a Pinnacle Lifetime Member for his contributions to Clinical Social Work. Dr. Jeffrey S. Yarvis, a distinguished clinical social worker, board-certified psychotherapist,...

Researchers from Allegheny Health Network (AHN), Baylor Scott & White Health, and Johns Hopkins Medicine have found that two newly approved immunotherapies can help to improve two-year survival rates for patients with...

It's National Sleep Awareness Month, and the American Massage Therapy Association (AMTA) is sharing the latest research on how massage can improve sleep quality. According to the Centers for Disease Control and Prevention (CDC), nearly 1 in 3 adults...

In the first clinical trial of a targeted pharmacologic therapeutic for mild traumatic brain injury in pediatric patients, scientists from the Minds Matter Concussion Frontier Program at Children's Hospital of Philadelphia (CHOP) have found...

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, announced today that it will present a talk and poster highlighting its novel chemistry technology platform for...

Mabwell (688062.SH), an innovative-driven biopharmaceutical company with entire industry chain, presented the clinical study data of the 9MW2821 for patients with cervical cancer as focused plenary oral presentation at the Society of Gynecologic...

FibroBiologics, Inc., ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived...

Verb Biotics, a microbiome health ingredient company, today announced preliminary preclinical data from their newly launched Keystone Postbiotictm, a foundational gut microbiome solution to help support and strengthen gut microbiome health....

The Bill & Melinda Gates Medical Research Institute (Gates MRI) today announced that a Phase...

Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel...

The Mesothelioma Center at Asbestos.com, the nation's most trusted resource for mesothelioma survivors and people diagnosed with other asbestos-related diseases, recently partnered with The Balancing Act on Lifetime TV....

Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today...

IceCure Medical Ltd. ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as...

Hoth Therapeutics, Inc. , is pleased to unveil positive pre-clinical  research showcasing the potential of HT-ALZ, an innovative Alzheimer's disease therapeutic. Targeting the Substance P/Neurokinin 1 Receptor pathway, HT-ALZ emerges as a promising...

Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, has launched an all-in-one package of contract research organization (CRO) services tailored for CNS, neurology, and psychiatric clinical...

ProofPilot, the industry's only platform for clinical trial automation, guidance and flawless execution, is excited to announce its strategic partnership with Verified Clinical Trials (VCT), the world's leading validated research participant registry...

Filament Health Corp. (NEO: FH) ("Filament" or the "Company"), a clinical?stage natural psychedelic drug development company, announced that since March 1, 2024 it has shipped its botanical psilocybin drug candidate, PEX010, to four countries for...

Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical leader in the...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today...

Maggie's Pearl, a collaboration between Perlara, Maggie's Cure, and the Mayo Clinic, announced that the Phase III trial of oral epalrestat therapy in pediatric subjects with PMM2-CDG (formerly, Congenital Disorder of Glycosylation Type 1a) has been...

NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced the publication of results in The Lancet Neurology from the pivotal, Phase 3 BouNDless trial (NCT04006210). Results from the trial, which...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of results in The Lancet Neurology from the pivotal, Phase 3 BouNDless trial (NCT04006210) evaluating the efficacy, safety and tolerability of investigational ND0612 ? a...

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") , a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that the U.S. Food and Drug Administration...

Mirimus, a pioneer in RNAi therapeutic design and CRISPR/Cas9 gene editing technology, proudly announces its role in advancing the development of HRX-215, a novel MKK4 inhibitor that showcases promising results in liver regeneration. This...

Johnson & Johnson announced today that new data will be featured at this year's European Lung Cancer Congress (ELCC) taking place from March 20 to 23 in Prague, Czech Republic, highlighting the Company's commitment to transform the treatment of lung...

Aquedeon Medical, Inc., a Silicon Valley pioneering medical device company specializing in novel cardiothoracic solutions, is pleased to announce a significant milestone with initiation of its investigational device exemption (IDE) clinical trial to...

On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as "chipscreen biosciences", stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for non-alcoholic...

KeChow Pharma, a commercial-stage pharmaceutical company focused on developing and commercializing differentiated small molecule therapeutics for cancer, today announced that the China National Medical Products Administration (NMPA) has approved...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today the Phase III clinical study results for its non-surgical treatment candidate for cervical high-grade...